AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

Intended Use: The HeartStart XL + is intended for use in a hospital setting by qualified medical personnel trained in the operation of the device and qualified by training in basic life support, advanced life support, or defibrillation. It must be used by or on the order of a physician.

When operating as a semi-automatic external defibrillator in AED Mode, the HeartStart XL+ is suitable for use by medical personnel trained in basic life support that includes use of an AED.

When operating in Monitor, Manual Defib or Pacer Mode, the HeartStart XL+ is suitable for use by healthcare professionals trained in advanced life support.

Indications for Use: The HeartStart XL+ is a defibrillator monitor. The device is for use by qualified medical personnel trained in the operation of the device and certified by training n basic life support, advanced life support or defibrillation. It must be used by or on the order of a physician.

AED Therapy: AED Mode is used in the presence of a suspected cardiac arrest on patients that are unresponsive, not breathing and pulseless.

Manual Defibrillation: Asynchronous defibrillation is the initial treatment for ventricular fibrillation and ventricular tachycardia in patients that are pulseless and unresponsive.

Synchronous defibrillation (cardioversion) is indicated for termination of atrial fibrillation.

Non-Invasive External Pacing: The pacing option is indicated for treating patients with symptomatic bradycardia.

Pulse Oximetry: The SpO2 option is indicated for use when it is beneficial to assess the patient's oxygen saturation level.

Non-invasive Blood Pressure Monitoring: The NBP option is indicated for non-invasive measurement of a patient's arterial blood pressure.

ECG Monitoring: The ECG monitoring option is indicated to be used for monitoring, alarming, and recording of the patient's heart rate and morphology.

Device Description

The HeartStart XL+ is a lightweight, portable defibrillator/monitor. It provides four clinical modes of operation: Monitor, Manual Defibrillator, AED and Pacer (optional).

In Monitor Mode, depending on the ECG inputs being used (pads, paddles, ECG cable), you can monitor up to 3 different ECG waveforms at one time. Using a 3-lead ECG cable you can view Lead I, II or III. With a 5-Lead ECG cable, you can view two leads from Leads I, III, avR, avF or V. Optional monitoring of SpO2 or NBP is available using existing and previously cleared technology as references in the predicate device comparison of the summary. Measurements are presented on the display and alarms are available to alert you to a change in the patient's condition. You can also display the Vital Signs Trending Report to view all key parameters and their measurements at a glance.

Manual Defibrillation Mode provides simple 1-2-3 defibrillation. You analyze the patient's ECG and, if appropriate: 1) select an energy setting; 2) charge; and 3) deliver the shock. Defibrillation is performed using paddles (internal or external) or multifunction electrode pads. You can also perform synchronized cardioversion in Manual Defibrillation Mode. The HeartStart XL+ incorporates Philips' low energy SMART Biphasic waveform for defibrillation which has been in use for over a decade.

In AED Mode, the HeartStart XL+ analyzes the patient's ECG and determines whether a shock is advised. Voice prompts guide you through the 2-step defibrillation process, with easy-to-follow instruction and patient information. Voice prompts are reinforced by messages on the display.

Optional Pacer Mode offers non-invasive transcutaneous pacing therapy. Pace pulses are delivered through multifunction electrode pads.

AI/ML Overview

The provided text describes the Philips HeartStart XL+ Defibrillator Monitor, a medical device. The submission primarily focuses on establishing substantial equivalence to predicate devices rather than presenting a performance study with explicit acceptance criteria for a new AI algorithm.

Therefore, the requested information regarding acceptance criteria, reported device performance, sample sizes, ground truth establishment, expert involvement, and MRMC studies, as they relate to a new AI algorithm or a distinct performance study, is not present in the provided document. The device is a defibrillator/monitor, and its "performance" is primarily assessed through compliance with recognized consensus standards and comparison to existing predicate devices.

However, I can extract information related to the device's technical specifications and the general approach to validating its equivalence.

Here's a breakdown of the available information in relation to your request:

1. A table of acceptance criteria and the reported device performance

This information is not explicitly stated as quantitative acceptance criteria for a new algorithm's performance in the document. Instead, the document focuses on compliance with established medical device standards and demonstrating equivalence to predicate devices. The "performance data" section states:

  • "Testing for performance was done according to applicable FDA recognized consensus standards for electrical defibrillation, ECG monitoring, SPO2 monitoring, and NBP monitoring."
  • "Additional standards testing beyond the list of FDA recognized standards was also performed."
  • "Small feature changes have been made to align the design with the 2010 AHA Resuscitation Guidelines. The previous product had only been evaluated against the 2005 AHA guidelines."

The document implies that the device "performs" by successfully meeting these standards and aligning with clinical guidelines, but it doesn't provide a table of numerical acceptance criteria or specific performance metrics (e.g., sensitivity, specificity for an AI component) in the way one would expect for a novel algorithmic claim.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

This information is not provided in the document. The testing mentioned refers to conformance with applicable standards, which typically involves laboratory testing and potentially some clinical evaluation, but no details on specific sample sizes for a "test set" are given.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This information is not provided in the document. Given the nature of the device (defibrillator/monitor) and the focus on standards compliance and predicate device equivalence, the concept of "ground truth established by experts" in the context of an algorithm's diagnostic performance (like in AI studies) doesn't directly apply here. Clinical validation would involve qualified medical personnel, but this is not detailed.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This information is not provided in the document.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

An MRMC study is not mentioned in the document. This is a medical device approval for a physical defibrillator/monitor, not an AI-assisted diagnostic tool for human readers.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

While the device includes internal algorithms (e.g., the HeartStream Patient Analysis System (PAS) Algorithm for AED mode), the document does not describe a "standalone" algorithmic performance study in the context of evaluating a new AI component. The algorithms integrated are existing and previously reviewed technologies, with the focus being on their integration into the new device and compliance with standards.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

This information is not explicitly stated in the document in the context of a new algorithm's performance. For a device like this, "ground truth" would implicitly come from established physiological measurements, validated clinical conditions (e.g., actual cardiac arrest for AED function), and adherence to recognized medical guidelines (AHA Resuscitation Guidelines).

8. The sample size for the training set

This information is not provided. The document does not describe the development or training of a new algorithm that would require a dedicated training set. It leverages existing, previously cleared algorithms like the HeartStream Patient Analysis System (PAS) Algorithm.

9. How the ground truth for the training set was established

This information is not provided. As above, the document focuses on integration of existing, cleared technologies rather than the development of a novel algorithm from scratch.

{0}------------------------------------------------

K110825

pg 1 of 7

FEB 16 2012

FEB 1 6 2012

5.0 510(k) Summary

As required by 21 CFR 807.87(h), a 510(k) Summary for this Premarket Notification submission is provided below. A 510(k) statement is therefore not required.

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

Philips Defibrillator Monitor

Submitter's Name and Address

Submitter's Name:Philips Medical Systems
Division:Emergency Care Solutions
Address:3000 Minuteman Road
City, State, and Zip:Andover, MA 01810
Contact Name:Paul Schrader, Senior Regulatory Affairs Manager
Telephone / Fax:(978) 659-2404 / 978-659-3610
510(k) Summary DateOctober 28, 2011

Manufacturers' Information: Establishment Registration Number

Establishment name:Philips Medical Systems
Address:3000 Minuteman RoadAndover, MA 01810
Establishment Registration No.1218950

{1}------------------------------------------------

||||0825

Image /page/1/Picture/1 description: The image shows a handwritten note on a white background. The note says "pg 2 of 7". The handwriting is somewhat cursive, and the ink appears to be dark. The image is simple and focuses solely on the handwritten text.

Device Details:

Proprietary or Trade Name:HeartStart XL +
Common Name:ALS Defibrillator Monitor
Device Class:III for AED mode (MKJ), II for theremaining applicable ProCodes / CFRclassifications
Device ProCodes:MKJ, LDD, DRO, DQA, DXN
Device CFR:Several see table below
Classification Panel:Cardiovascular
21 CFR Classification Name /DescriptionSeveral see table below
ClassificationProCodeClassification Description
870.5310-IIIMKJDefibrillators, Automatic, External
870.5300-IILDDLow-energy defibrillator1
870.5550-IIDROExternal Transcutaneous Pacemaker(Non-invasive)
870.2700-IIDQAPulse Oximeter
870.1130-IIDXNNon-Invasive Blood Pressure
870.1025-IIMHXArrhythmia detector and alarm

{2}------------------------------------------------

Device Name: Philips XL+ Defibrillator Monitor

Intended Use: The HeartStart XL + is intended for use in a hospital setting by qualified medical personnel trained in the operation of the device and qualified by training in basic life support, advanced life support, or defibrillation. It must be used by or on the order of a physician.

When operating as a semi-automatic external defibrillator in AED Mode, the HeartStart XL+ is suitable for use by medical personnel trained in basic life support that includes use of an AED.

When operating in Monitor, Manual Defib or Pacer Mode, the HeartStart XL+ is suitable for use by healthcare professionals trained in advanced life support.

Indications for Use: The HeartStart XL+ is a defibrillator monitor. The device is for use by qualified medical personnel trained in the operation of the device and certified by training n basic life support, advanced life support or defibrillation. It must be used by or on the order of a physician.

AED Therapy: AED Mode is used in the presence of a suspected cardiac arrest on patients that are unresponsive, not breathing and pulseless.

Manual Defibrillation: Asynchronous defibrillation is the initial treatment for ventricular fibrillation and ventricular tachycardia in patients that are pulseless and unresponsive.

Synchronous defibrillation (cardioversion) is indicated for termination of atrial fibrillation.

Non-Invasive External Pacing: The pacing option is indicated for treating patients with symptomatic bradycardia.

Pulse Oximetry: The SpO2 option is indicated for use when it is beneficial to assess the patient's oxygen saturation level.

Non-invasive Blood Pressure Monitoring: The NBP option is indicated for non-invasive measurement of a patient's arterial blood pressure.

ECG Monitoring: The ECG monitoring option is indicated to be used for monitoring, alarming, and recording of the patient's heart rate and morphology.

{3}------------------------------------------------

Device Description

The HeartStart XL+ is a lightweight, portable defibrillator/monitor. It provides four clinical modes of operation: Monitor, Manual Defibrillator, AED and Pacer (optional).

In Monitor Mode, depending on the ECG inputs being used (pads, paddles, ECG cable), you can monitor up to 3 different ECG waveforms at one time. Using a 3-lead ECG cable you can view Lead I, II or III. With a 5-Lead ECG cable, you can view two leads from Leads I, III, avR, avF or V. Optional monitoring of SpO2 or NBP is available using existing and previously cleared technology as references in the predicate device comparison of the summary. Measurements are presented on the display and alarms are available to alert you to a change in the patient's condition. You can also display the Vital Signs Trending Report to view all key parameters and their measurements at a glance.

Manual Defibrillation Mode provides simple 1-2-3 defibrillation. You analyze the patient's ECG and, if appropriate: 1) select an energy setting; 2) charge; and 3) deliver the shock. Defibrillation is performed using paddles (internal or external) or multifunction electrode pads. You can also perform synchronized cardioversion in Manual Defibrillation Mode. The HeartStart XL+ incorporates Philips' low energy SMART Biphasic waveform for defibrillation which has been in use for over a decade.

In AED Mode, the HeartStart XL+ analyzes the patient's ECG and determines whether a shock is advised. Voice prompts guide you through the 2-step defibrillation process, with easy-to-follow instruction and patient information. Voice prompts are reinforced by messages on the display.

Optional Pacer Mode offers non-invasive transcutaneous pacing therapy. Pace pulses are delivered through multifunction electrode pads.

{4}------------------------------------------------

redicate Device Comparison: Previous Philips Defibrillator Monitors

Specification / Clinical FunctionHeartStart XLHeartStart MRxPhilips HeartStart XL+Complies w/IEC 60601-2-4:2005 &monitoring standardslisted belowComparisonPredicate 510(k) #s
Defibrillation WaveformBi-phasic 1 – 200 JoulesBi-phasic 1 – 200 JoulesSame design asHeartStart XL andHeartStart MRxK001725 HeartStart XLK031187 HeartStart MRxK001725 HeartStart XL K031187HeartStart MRx
Defibrillation ModesManual and AEDManual and AEDPediatrics has been addedby using previouslyreviewed algorithm andpadsK001725 HeartStart XL (Adult)K031187 HeartStart MRx (Adult)K003819 FR2 (Pediatrics)
AED ModesAdultsAdults and PediatricsPhilips has standardizedon use of the PASalgorithm.K954597 HP Shock Advisory (Adult)K955628 PAS Algorithm (Adult)K003819 PAS Algorithm (Pediatrics)
Shock Advisory AlgorithmHewlett-Packard Shock AdvisoryHeartStream Patient Analysis System (PAS) AlgorithmSame waveform as MRxK010634 Cardioversion added to XLK031187 HeartStart MRx
CardioversionAvailableAvailableSame waveform as MRxK001725 HeartStart XLK031187 HeartStart MRx
External PacingYes w/ PadsYes w/ Pads
Specification / Clinical FunctionHeartStart XL HeartStart MRxPhilips HeartStart XL+ Complies w/ IEC 60601-2-4:2005 & monitoring standards listed belowComparisonPredicate 510(k) #s
Pads and Paddles
PadsSeveral different pads as listed in predicate list in the last columnNo change in pad construction from pads currently used with HeartStart XL/MRxSame pads as currently being used with HeartStart MRX and HeartStart XL. Labeling changed to standardize format and content for whole family. One IFU created for three different groupings: infant pads (previously called pediatric pads), adult pads and adult preconnect pads.Infant Pads:M3504A:K992977M3717A:K003228M3719A (Radiotransparent): K0012218Adult / Child Pads:M3501A: K991871M3713A: K002806M3716A (Radiolucent): K002806M3718A (Radiotransparent): K002806989803166021(Preconnect): K002806
PaddlesInternal and ExternalComplies w/ IEC 60601-2-4:2005No change to internal paddles. External paddles were modified to allow use of inter-changeable electrode selected on patient size. Customer no longer needs two separate external paddles.K021453 Internal PaddlesK001725 External Paddles
MONITORING
ECG monitoringTested to 60601-2-27Complies w/ IEC 60601-2-27: 2005Available on both XL and MRx, design is leveraged from MRxK031187 HeartStart MRx
SPO2 monitoringTested to ISO 9919Complies w/ ISO 9919:2005Available on both XL and MRx, acquisition and processing of SPO2 data has not changed from MRxK031187 HeartStart MRx
NBP monitoringTested to 60601-2-30 on MRx, Not available w/ XLComplies w/ IEC 60601-2-30: 1999acquisition and processing of SPO2 data has not changed from MRxK031187 HeartStart MRx

{5}------------------------------------------------

K110825 pg 6 of 7

{6}------------------------------------------------

Performance Data

The HeartStart XL + has all of the major features of the HeartStart XL plus the additional feature of NBP monitoring. Testing for performance was done according to applicable FDA recognized consensus standards for electrical defibrillation, ECG monitoring, SPO2 monitoring, and NBP monitoring. Additional standards testing beyond the list of FDA recognized standards was also performed. Small feature changes have been made to align the design with the 2010 AHA Resuscitation Guidelines. The previous product had only been evaluated against the 2005 AHA guidelines.

Conclusions

The HeartStart XL + is substantially equivalent to previous Philips defibrillator monitor products and accessories. The predicates HeartStart FR2, HeartStart MRx have been commercially distributed and successfully used for several years.

Product design and testing was done in conformance with FDA-recognized standards. Conformance with recognized standards ensures product design and function will address known issues related to safety and effectiveness.

Based on similarity in technology, characteristics and indications for use as the predicate, the Philips defibrillator monitors (new and predicate) described in this summary are substantially equivalent.

{7}------------------------------------------------

Image /page/7/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The logo is black and white.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring. MD 20993-0002

FEB 1 6 2012

Philips Healthcare c/o Mr. Paul Schrader Senior Regulatory Affairs Manager 3000 Minuteman Road Andover, MA 01810

Re: K110825

Trade/Device Name: Philips Heartstart XL+, Philips External Paddles, Philips Multifunction Electrodes Regulation Number: 21 CFR 870.5310 Regulation Name: Automated External defibrillator Regulatory Class: Class III Product Code: MKJ, LDD, DRO, DQA, DXN, MHX Dated: February 3, 2012 Received: February 6, 2012

Dear Mr. Schrader:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

{8}------------------------------------------------

Page 2 - Mr. Paul Schrader

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

  • Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (2) CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
    If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

A-Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

{9}------------------------------------------------

K110825 pg lofl

4.0 Indications for Use Statement .

510(k) Number:

Device Name: Philips XL+ Defibrillator Monitor Indications for Use:

Intended Use:

The HeartStart XL + is intended for use in a hospital setting by qualified medical personnel trained in the operation of the device and qualified by training in basic life support, advanced life support, or defibrillation. It must be used by or on the order of a physician.

When operating as a semi-automatic external defibrillator in AED Mode, the HeartStart XL+ is suitable for use by medical personnel trained in basic life support that includes use of an AED.

When operating in Monitor, Manual Defib or Pacer Mode, the HeartStart XL+ is suitable for use by healthcare professionals trained in advanced life support.

Indications for Use:

The HeartStart XL+ is a defibrillator monitor. The device is for use by qualified medical personnel trained in the operation of the device and certified by training in basic life support, advanced life support or defibrillation. It must be used by or on the order of a physician.

AED Therapy

AED Mode is used in the presence of a suspected cardiac arrest on patients that are unresponsive, not breathing and pulseless.

Manual Defibrillation

Asynchronous defibrillation is the initial treatment for ventricular fibrillation and ventricular tachycardia in patients that are pulseless and unresponsive.

Synchronous defibrillation (cardioversion) is indicated for termination of atrial fibrillation. Non-Invasive External Pacing

The pacing option is indicated for treating patients with symptomatic bradycardia. Pulse Oximetry

The SpO2 option is indicated for use when it is beneficial to assess the patient's oxygen saturation level.

Non-invasive Blood Pressure Monitoring

The NBP option is indicated for non-invasive measurement of a patient's arterial blood pressure. ECG Monitoring

The ECG monitoring option is indicated to be used for monitoring, alarming, and recording of the patient's heart rate and morphology.

Prescription Use(21 CFR 801 Subpart D)XAND/OR
-------------------------------------------------------

Over-The-Counter Use (21 CFR 801 Subpart C)

unter Use
Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NECESSARY)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Cardiovascular Devices

510(k) Number K1108

§ 870.5310 Automated external defibrillator system.

(a)
Identification. An automated external defibrillator (AED) system consists of an AED and those accessories necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock (e.g., battery, pad electrode, adapter, and hardware key for pediatric use). An AED system analyzes the patient's electrocardiogram, interprets the cardiac rhythm, and automatically delivers an electrical shock (fully automated AED), or advises the user to deliver the shock (semi-automated or shock advisory AED) to treat ventricular fibrillation or pulseless ventricular tachycardia.(b)
Classification. Class III (premarket approval)(c)
Date PMA or notice of completion of PDP is required. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED that was in commercial distribution before May 28, 1976. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976. Any other AED and AED accessory described in paragraph (a), shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.